video: Low-dose ketamine produces long-term reduction in levodopa-induced dyskinesia
A multicenter, double-blind, placebo-controlled Phase II/III trial (NCT04912115), with midazolam as an active-placebo, is planned to start before the end of the year. This interview took place at the 2022 International Congress of Parkinson’s Disease and Movement Disorders in Madrid, Spain.
A multicenter, double-blind, placebo-controlled Phase II/III trial (NCT04912115), with midazolam as an active-placebo, is planned to start before the end of the year. This interview took place at the 2022 International Congress of Parkinson’s Disease and Movement Disorders in Madrid, Spain.